

ASX ANNOUNCEMENT

Associate Professor Craig Lewis appointed Chief Medical Adviser

Sydney Australia, 17 March 2014: RNAi-based gene silencing therapeutics company Benitec Biopharma Limited (ASX Code: BLT), today advised that Dr Craig Lewis has agreed to serve as Chief Medical Adviser (part-time) on the company's non-small cell lung cancer (NSCLC) program.

Dr Lewis is a medical oncologist at Sydney's Prince of Wales Hospital. His major areas of interest are in clinical trial research in lung and breast cancer, and sarcoma. Another area of interest is cancer pain management.

Dr Lewis is a Fellow of the Royal Australasian College of Physicians, a member of the Medical Oncology Group of Australia, the American Society of Clinical Oncology, and the Clinical Oncological Society of Australia. He holds a conjoint appointment in the School of Medicine at the University of New South Wales at the Associate Professor level.

Dr Lewis commented on the announcement saying, "I am very excited to join Benitec at this stage of its clinical development in NSCLC. Benitec's ddRNAi technology has significant potential to be a breakthrough approach for this and many other diseases which is why it is important to test its efficacy and safety in the clinic. I am looking forward to assisting Benitec in that process."

Benitec's Managing Director and CEO Dr Peter French commented, "It is very pleasing to have Dr Lewis advising on NSCLC, and his appointment further demonstrates our commitment to properly resourcing programs in clinical development."

For more information please contact:

Dr Peter French | Managing Director and Chief Executive Officer

Phone: +61 (02) 9555 6986 | pfrench@benitec.com | www.benitec.com

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.